ResApp Health has reported positive data from clinical trials of its new cough audio-based Covid-19 screening test.

The new Covid-19 instant screening test, which requires only a smartphone, uses cough sounds to detect the presence of infection.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It uses machine learning to analyse a patient’s cough sound and measure the severity of respiratory conditions without using any additional accessories or hardware.

The company’s new test showed 92% sensitivity for detecting Covid-19 in a pilot clinical trial.

The trial was conducted with 741 participants, including 446 Covid-19 positive patients, recruited in India and the US.

ResApp intends to initially target market opportunities where frequent Covid-19 testing is required, including travel, entertainment, healthcare worker, student screening, sports, employee and aged care markets.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It expects the new smartphone-based test to reduce costs, environmental impact and the number of rapid antigen or PCR tests required, as well as improve test availability.

The test can also improve security and results reporting by using biometric identification, such as facial recognition.

ResApp CEO and managing director Tony Keating said: “These algorithms offer a unique opportunity to provide a rule out screening test for Covid-19 at scale across the world, reducing the distribution challenge, the cost and the environmental impact of rapid antigen and PCR testing.

“We intend to accelerate commercialisation by immediately engaging with regulators globally, and we have already commenced discussions with global health and technology companies with the goal of rapidly bringing this product to market.”

The company said that the new cough audio-based algorithm was tested against the Breathe Easy dataset to ensure that it was specific to Covid-19.